{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene+glycol+%28PEG%29", "query": { "intervention": "Polyethylene glycol (PEG)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 354, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene+glycol+%28PEG%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T18:05:19.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00889655", "title": "A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colonoscopy" ], "interventions": [ { "name": "Golytely (polyethylene glycol)", "type": "DRUG" }, { "name": "MiraLax (polyethylene glycol 3350)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 432, "start_date": "2009-05", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2009-04-29", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889655" }, { "nct_id": "NCT00501826", "title": "Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Acute Lymphoblastic Leukemia", "T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 160, "start_date": "2007-07-11", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501826" }, { "nct_id": "NCT06598007", "title": "A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "CT3001", "type": "DRUG" }, { "name": "FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crossignal Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2024-09-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598007" }, { "nct_id": "NCT03202927", "title": "Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "PEGFILGRASTIM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adello Biologics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 102, "start_date": "2017-03-25", "completion_date": "2018-04-12", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 2, "location_summary": "Tempe, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03202927" }, { "nct_id": "NCT03247595", "title": "Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colonoscopy" ], "interventions": [ { "name": "Magnesium Citrate Capsules", "type": "DIETARY_SUPPLEMENT" }, { "name": "Polyethylene Glycol 3350", "type": "OTHER" }, { "name": "Dulcolax Tablets", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "LifeBridge Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-09-26", "completion_date": "2020-06-16", "has_results": false, "last_update_posted_date": "2021-03-09", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247595" }, { "nct_id": "NCT03531827", "title": "Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer", "Prostate Neoplasms" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" }, { "name": "CRLX101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2019-03-26", "completion_date": "2021-06-01", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03531827" }, { "nct_id": "NCT04789044", "title": "Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Nerve Injuries" ], "interventions": [ { "name": "NTX-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Major Extremity Trauma Research Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2023-06-01", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 7, "location_summary": "Baltimore, Maryland • Camden, New Jersey • Charlotte, North Carolina + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "York", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04789044" }, { "nct_id": "NCT00008463", "title": "A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Interferon alfa-2a", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 132, "start_date": "2000-11", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 24, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008463" }, { "nct_id": "NCT06132165", "title": "Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis 1" ], "interventions": [ { "name": "Deoxycholic Acid", "type": "DRUG" }, { "name": "Polidocanol", "type": "DRUG" }, { "name": "1064nm Nd:YAG laser", "type": "DEVICE" }, { "name": "755nm Alexandrite Laser", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 13, "start_date": "2024-03-01", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06132165" }, { "nct_id": "NCT00160602", "title": "A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2005-06", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2020-12-01", "last_synced_at": "2026-09-26T18:05:19.400Z", "location_count": 17, "location_summary": "Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160602" } ] }